The partnership will help to accelerate the development and manufacturing of Clover's protein-based S-Trimer subunit vaccine candidate. The candidate showed promising preliminary results in a phase I clinical study, according to the company.

Clover upstream current good manufacturing practice manufacturing site in Zhejiang, China. Image courtesy of Cytiva.

Clover aims to expand the Cytivia FlexFactory capacity from 2 x 2,000 L to 4 x 2,000 L with the addition of two 2,000-L bioreactors. The factory will process equipment, services, and consumables for vaccine development in order to meet Clover's phase II/III clinical production plan as well as to reach commercial readiness should a vaccine be approved.

Clover touts positive preclinical results for COVID-19 vaccine
Clover Biopharmaceuticals has announced positive preclinical data regarding its protein-based COVID-19 S-Trimer vaccine candidate in combination with...

CEPI expands Clover partnership on COVID-19 vaccine
The Coalition for Epidemic Prepardeness Innovations (CEPI) has expanded its partnership with Clover Biopharmaceuticals for the development and manufacture...

CEPI, Clover to partner on COVID-19 vaccine
The Coalition for Epidemic Preparedness Innovations (CEPI) and Clover Biopharmaceuticals Australia plan to partner on the development of a COVID-19 vaccine.

COVID-19 vaccine candidates show progress amid challenges
As the COVID-19 outbreak advances worldwide, companies are stepping up to the challenge to develop a potential vaccine. There are over 75 confirmed COVID-19...